ICIs such as PD-1, PDL-1, and CTLA-4 antibodies can restore anti-tumor immune response by antagonizing T cell activation inhibitory molecules and promoting T cell recognition of tumors [16–18]. Here, CTLA4 is linked to neoplasm.